Exploring TruVivo®, Enhancing Liver Disease Studies with an All-Human 2D+ Hepatic System
Jessica Weaver, PhD, from LifeNet Health LifeSciences will lead the discussion, highlighting how TruVivo:
- Enables prolonged maintenance of primary human hepatocytes derived from diseased livers.
- Retains key features of MAFLD, including steatosis, inflammation, and fibrosis markers.
- Was used to investigate Obeticholic acid’s (OCA) impact of lipogenesis and bile acid transport.